4/A: Collegium Pharmaceutical EVP Scott Dreyer Corrects Transaction Date in Form 4 Amendment
SEC Filing
Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, files an amended Form 4 to correct the transaction date of a sale of common stock.
Summary
- Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, filed an amendment to his Form 4 to correct the transaction date.
- The original Form 4, filed on March 13, 2025, incorrectly reported the transaction date.
- The corrected transaction date is March 11, 2025.
- On March 11, 2025, Dreyer sold 15,387 shares of Collegium Pharmaceutical common stock at a weighted average price of $30.004.
- The sales were executed under a Rule 10b5-1 trading plan adopted on August 28, 2024.
- Following the transaction, Dreyer beneficially owns 126,676 shares of Collegium Pharmaceutical common stock.
Sentiment
Score: 5
Explanation: The document is a routine correction of a regulatory filing, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor executive compensation and potential alignment of interests.
Stakeholder Impact
- Shareholders benefit from accurate and transparent reporting of insider transactions.
Key Dates
| Date | Description |
|---|---|
| 2024-08-28 | Date of adoption of Rule 10b5-1 trading plan |
| 2025-03-11 | Corrected transaction date of stock sale |
| 2025-03-13 | Date of original Form 4 filing with incorrect transaction date |
| 2025-03-18 | Date of Form 4/A filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.